Research Article
Gender Disparity in the Relationship between Prevalence of Thyroid Nodules and Metabolic Syndrome Components: The SHDC-CDPC Community-Based Study
Table 2
Stratified analysis of prevalence of thyroid nodules according to the different levels of metabolic syndrome components.
| | Parameters | Total subjects () | Males () | Females () | | Thyroid nodules | Nonthyroid nodules | Thyroid nodules | Nonthyroid nodules | Thyroid nodules | Nonthyroid nodules |
| | Age (years) | | | | | | | | <55 | 540 (24.1) | 1700 (75.9) | 194 (18.5) | 854 (81.5) | 346 (29.0) | 846 (71.0) | | 55–65 | 912 (34.2) | 1756 (65.8) | 362 (27.2) | 967 (72.8) | 550 (41.1) | 789 (58.9) | | 65–75 | 497 (39.4) | 765 (60.6) | 203 (32.3) | 426 (67.7) | 294 (46.5) | 339 (53.6) | | ≥75 | 252 (41.0) | 362 (59.0) | 93 (34.1) | 180 (65.9) | 159 (46.6) | 182 (53.4) | | Chi-square | 123.139 | 53.725 | 75.329 | | value | <0.001 | <0.001 | <0.001 | | for trend | <0.001 | <0.001 | <0.001 | | BMI (kg/m2) | | | | | | | | <25.0 | 1270 (32.8) | 2602 (67.2) | 465 (26.1) | 1319 (73.9) | 805 (38.6) | 1283 (61.5) | | 25.0–30.0 | 755 (32.1) | 1601 (68.0) | 314 (25.3) | 929 (74.7) | 441 (39.6) | 672 (60.4) | | ≥30.0 | 122 (32.5) | 254 (67.6) | 48 (28.9) | 118 (71.1) | 74 (35.2) | 136 (64.8) | | Chi-square | 0.380 | 1.076 | 1.479 | | P value | 0.827 | 0.584 | 0.477 | | P for trend | 0.618 | 0.888 | 0.806 | | WHR | | | | | | | | Q1 | 504 (31.1) | 1115 (68.9) | 187 (24.0) | 593 (76.0) | 317 (37.8) | 522 (62.2) | | Q2 | 515 (31.8) | 1105 (68.2) | 196 (24.7) | 597 (75.3) | 319 (38.6) | 508 (61.4) | | Q3 | 520 (32.1) | 1099 (67.9) | 203 (26.3) | 568 (73.7) | 317 (37.4) | 531 (62.6) | | Q4 | 544 (33.9) | 1062 (66.1) | 208 (26.8) | 567 (73.2) | 336 (40.4) | 495 (59.6) | | Chi-square | 3.034 | 2.222 | 1.941 | | value | 0.386 | 0.528 | 0.585 | | for trend | 0.101 | 0.144 | 0.372 | | Waist circumference (cm) | | | | | | | | <90 in men | 812 (29.3) | 1964 (70.8) | 454 (25.1) | 1356 (74.9) | 358 (37.1) | 608 (62.9) | | <80 in women | | ≥90 in men | 1281 (34.6) | 2425 (65.4) | 345 (26.2) | 973 (73.8) | 936 (39.2) | 1452 (60.8) | | ≥80 in women | | Chi-square | 20.506 | 0.479 | 1.324 | | value | <0.001 | 0.489 | 0.250 | | HOMA-IR | | | | | | | | <2.8 | 1603 (31.0) | 3566 (69.0) | 649 (24.9) | 1954 (75.1) | 954 (37.2) | 1612 (62.8) | | ≥2.8 | 597 (37.0) | 1016 (63.0) | 203 (30.1) | 472 (69.9) | 394 (42.0) | 544 (58.0) | | Chi-square | 20.194 | 7.366 | 6.758 | | value | <0.001 | 0.001 | 0.009 | | Glucose metabolic status | | | | | | | | NGR, (%) | 472 (29.9) | 1106 (70.1) | 195 (26.1) | 652 (73.9) | 277 (33.3) | 554 (66.7) | | Prediabetes, (%) | 1094 (31.4) | 2390 (68.6) | 397 (24.1) | 1248 (75.9) | 697 (37.9) | 1142 (62.1) | | Diabetes, (%) | 526 (37.2) | 889 (62.8) | 208 (28.8) | 515 (71.2) | 318 (46.0) | 374 (54.1) | | Chi-square | 20.773 | 5.746 | 25.896 | | value | <0.001 | 0.057 | <0.001 | | for trend | <0.001 | 0.253 | <0.001 | | UA (μmol/l) | | | | | ≤420 in men | 1856 (32.5) | 3862 (67.5) | 702 (26.6) | 1933 (73.4) | 1154 (37.4) | 1929 (62.6) | | ≤360 in women | | >420 in men | 341 (32.2) | 719 (67.8) | 150 (23.4) | 492 (76.6) | 191 (45.7) | 227 (54.3) | | >360 in women | | Chi-square | 0.034 | 2.881 | 10.622 | | value | 0.854 | 0.090 | 0.001 | | NAFLD | | | | | Without NAFLD | 760 (32.2) | 1599 (67.8) | 254 (26.3) | 713 (73.7) | 506 (36.4) | 886 (63.7) | | NAFLD | 535 (33.4) | 1069 (66.7) | 214 (26.0) | 610 (74.0) | 321 (41.2) | 459 (58.9) | | Chi-square | 0.561 | 0.020 | 4.892 | | value | 0.454 | 0.887 | 0.027 | | Metabolic syndrome | | | | | Without MetS | 1168 (30.1) | 2716 (69.9) | 539 (25.6) | 1566 (64.3) | 629 (35.4) | 1150 (64.6) | | MetS | 876 (35.3) | 1605 (64.7) | 249 (25.8) | 716 (74.2) | 627 (41.4) | 889 (58.6) | | Chi-square | 19.041 | 0.014 | 12.500 | | value | <0.001 | 0.908 | <0.001 |
|
|
BMI, body mass index; WHR, waist-to-hip ratio; NGR, normal glucose regulation; UA, uric acid; NAFLD, nonalcoholic fatty liver disease; MetS, metabolic syndrome.
|
